Trial Profile
Apatinib for Advanced Soft Tissue Sarcoma Patients After Failure of Traditional Therapy: an One-armed, Phase 2, Open-label, Multicenter Prospective Trial
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 20 May 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 15 May 2020 Status changed to withdrawn prior to enrolment. .
- 04 Mar 2020 Status changed from suspended to completed.
- 05 Feb 2020 Status changed from recruiting to suspended.